Inflammatory breast cancer

Ricardo Hugo Alvarez*, Shaheenah Dawood, Massimo Cristofanilli

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer, with the optimal treatment methods remaining a challenge, primarily due to the early onset of metastasis and rapid tumor progression. In the United States, the incidence is low, reported as 1–6 % of all breast cancers. Data from the Surveillance, Epidemiology, and End Results Program (SEER) revealed that IBC incidence rates between 1988–1990 and 1997–1999 increased from 2 to 2.5 (per 100,000 women-years) (p<0.001), whereas those with locally advanced breast cancer (LABC) declined (2.5–2.0; p=0.0025). Improvement in systemic treatment and locoregional managements with surgery and radiation are a crucial part of the curative treatment program of IBC, and several studies have shown the improvement in locoregional control and overall survival when patients are treated with chemotherapy. However, despite the use of multidisciplinary treatment for the IBC, the 5-year survival remains at approximately 30–40 %, with no significant change in the overall prognosis over the past 30 years.

Original languageEnglish (US)
Title of host publicationBreast disease
Subtitle of host publicationComprehensive management
PublisherSpringer New York
Number of pages13
ISBN (Electronic)9781493911455
ISBN (Print)9781493911448
StatePublished - Jan 1 2015


  • Inflammatory breast cancer
  • Primary systemic therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Inflammatory breast cancer'. Together they form a unique fingerprint.

Cite this